Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2019-003002-27Phase 3Completed
Phase 3, open-label, single-arm trial of estetrol + drospirenone in menstrual disorders, sponsored by Estetra SRL. Primary endpoint: Treatment-emergent adverse events. Started Apr 2020; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2019-003002-27.